SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2020-02-20 , DOI: 10.1200/jco.2020.38.6_suppl.90
Xiaojian Qin ₁ , Weiqing Han ₂ , Hong Luo ₃ , Chuanjun Du ₄ , Qing Zou ₅ , Zhongquan Sun ₆ , Chaohong He ₇ , Shaoxing Zhu ₈ , Tie Chong ₉ , Xin Yao ₁₀ , Ben Wan ₁₁ , Weijie Gu ₁₂ , Dingwei Ye ₁₂

Affiliation

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China;
Hunan Cancer Hospital, Changsha, China;
Chongqing Cancer Hospital, Chongqing, China;
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, China;
Jiangsu Cancer Hospital, Jiangsu, China;
Huadong Hospital Affiliated to Fudan University, Shanghai, China;
Cancer Hospital of Henan Province, Zhengzhou, China;
Zhejiang Cancer Hospital, Hangzhou, China;
Department of Urology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China;
Tianjin Cancer Hospital, Tianjin, China;
Department of Urology, Beijing Hospital, Beijing, China;
Fudan University Shanghai Cancer Center, Shanghai, China;

90Background: SHR3680 is a novel and pure androgen-receptor (AR) antagonist that shows a potent antitumor activity against CRPC but with much less brain distribution than enzalutamide in preclinica...

中文翻译：